Skip to content

An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease

An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02406105
Enrollment
27
Registered
2015-04-02
Start date
2015-01-31
Completion date
2020-12-31
Last updated
2015-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

tremor, Parkinson disease, functional radioablation, Cyber Knife radiosurgery

Brief summary

Clinical objective of the study is estimation of effectiveness and safety of Cyber Knife based functional radiosurgery for Parkinson disease patients suffering from tremor.

Detailed description

Basic treatment patients with Parkinson's disease (PD - Parkinson's disease) or essential tremor (ET - essential tremor) is a pharmacotherapy. In the case of lack of its effectiveness, the gold standard procedure is deep brain stimulation (DBS). Despite the proven efficacy, still remains a group of patients not eligible for this treatment. in such cases, ablation within the deep structures of the brain (thalamotomy, subthalamotomy, pallidotomy) can be considered. Thermoablation and radiosurgery (SRS - Stereotactic radiosurgery) are used: SRS is prefered for patients who are not candidates for invasive procedures. 27 patients will be enrolled in this study. All patients will be immobilized in thermoplastic masks and planned (RT) on the base of CT/MRI fusion. The initial total dose in the target volume (thalamic nuclei complex - VoP and VoA ) will be 70 Gy given in one fraction. The dose will be escalated every 5 Gy and the treatment effect and possible side effects will be evaluated. Dose escalation will be finished at a dose at which the effect of treatment will be satisfactory, or if side effects are unacceptable. The highest dose tested dose will be 110 Gy. Three patients will be irradiated with particular doses and observed at least 3 moths; then study will be continued. Patients will be controlled 3, 6, 9, 12, 18 months after treatment completion and, next every each 6 months. Neurologic and neuropsychologic status, local effect (MRI ) and eventual toxicity will be checked during follow-up (FU).

Interventions

Cybernetic microradiosurgery based thalamotomy

Sponsors

Maria Sklodowska-Curie National Research Institute of Oncology
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Idiopatic Parkinson Disease (PD) * Lack of effective pharmacotherapy * Lack of possibilities of qualifications to DBS (deep brain stimulation) procedure * Informed consent for participation in the study and for radiotherapy

Exclusion criteria

* Age under 18 * Pregnancy * Other than PD induced tremor * Dementia, psychosis. * Poor performance status * Atrophic cerebral changes, structural changes in basal nuclei * Lack of informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Tremor reduction evaluated using Unified Parkinson's Disease Rating Scale1 yearTremor reduction will be evaluated using Unified Parkinson's Disease Rating Scale (UDPRS)

Secondary

MeasureTime frameDescription
Safety of treatment (evaluated using RTOG/EORTC Acute Radiation Morbidity Scoring Criteria and Late Radiation Morbidity Scoring Schema)1 yearSafety of treatment will be evaluated using RTOG/EORTC Acute Radiation Morbidity Scoring Criteria and Late Radiation Morbidity Scoring Schema
Evaluation of the value of magnetic resonance spectroscopy as a tool for metabolites proportions changes after PD radiosurgery (spectra of metabolites in irradiated volume)2 yearsNone grading system of serial spectroscopy dedicated for such purpose exists. We will check spectra of metabolites in irradiated volume and proportions between them, trying to form conclusions considering necrosis/gliosis forming.
Implementation of CyberKnife radiosurgery for Parkinson disease patients not eligible for other treatment modality2 years

Countries

Poland

Contacts

Primary ContactLeszek Miszczyk, MD, PhD
leszek@io.gliwice.pl0048322788001

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026